HOW IT FITS YOUR WORKFLOW
Four steps. No disruption.
STEP 01
Connect
CystoAID® plugs into your existing setup via a dedicated medical PC, enabling the software to be deployed during cystoscopy.
STEP 02
Inspect
Start the procedure as normal. CystoAID® runs on-premise with an on/off option.
STEP 03
Detect
Suspected lesions in the field of view are digitally marked.
STEP 04
Decide
Detection support helps you separate benign from malignant at the point of decision, not after pathology.
DETECTION CHALLENGE
Can you identify the lesion?
Conventional white-light cystoscopy remains the state of the art in bladder cancer care, but missed lesions remain a recognized clinical challenge. CystoAID® is your objective assistant, analyzing the live feed and highlighting suspected areas in real time for both flexible and rigid cystoscopy.
In 2021, a survey of 60 Danish urologists showed that...
71%
found AI-assisted bladder cancer detection relevant
93%
reported difficulty differentiating cancer from inflammation
98%
stated they could not distinguish low- from high-grade tumors
DURING THE PROCEDURE
What you see on the monitor.
01 · DETECTION
Digital markings appear only when the model is confident.
CystoAID® highlights detected lesions. No full-screen overlays, no flashing – just the same visual language your team already uses to annotate clinical video.
02 · MULTI-LESION TRACKING
Every area of interest. Concurrently. Consistently.
CystoAID® detects multiple lesions in the same field of view, addressing the clinical challenge of surveillance in recurrent disease.
VALUE
Identify more tumors.
→ fewer surgeries.
CystoAID® is your intelligent AI assistant, designed to support visual interpretation during cystoscopy with more consistent and objective assessment - without adding steps or data handling burden.
The goal: aiming to improve patient outcomes, fewer unnecessary procedures, and measurable cost savings across the care pathway.
Up to 45%
Potential reduction in unnecessary surgical procedures.
INTERNAL MODEL-BASED ESTIMATES · BASED ON RAISE01 FP REDUCTION
Up to 20%
Potential reduction in total cost of bladder cancer care.
CYSTOTECH ESTIMATES BASED ON unpublished data · FEWER PROCEDURES + ANESTHESIA SHIFT
25% → 5%
Diagnostic false-positive rate – from unaided cystoscopy to CystoAID-assisted.
GROSSMAN ET AL. · CYSTOAID SOLUTION TARGET
Potential impact.
FOR THE PATIENT
Improved outcome, higher quality of life.
Improved personalized treatment
Fewer hospital visits
Decreased uncertainty and less burdensome repeated invasive procedures
FOR THE CLINICIAN
Objective support, unchanged workflow.
Real-time second opinion during the procedure
Procedure consistency and performance
No change in clinical workflow
FOR THE HOSPITAL
Lower cost per patient, better throughput.
Optimized patient pathway
Fewer readmission events
State-of-the-art technology
FOR THE HEALTHCARE SYSTEM
Improving the care pathway.
Measurable impact on the $12B annual EU + US care burden
Increased operating efficiencies
Compelling health economic case
EVIDENCE
Proof before position.
Every claim, cited.
CystoAID® has been developed under a formal clinical investigation program. RAISE01 and RAISE02 have been completed, and a pivotal international RCT is initiated in 2026.
→ RAISE03 – Enrollment H2 2026
88.1%
Positive Predictive Value (95% CI: 81.3% – 92.7%)
71
Real-world procedures analyzed
437,244
Video frames included in analysis
HEADLINE RESULTS · RAISE01 REAL-WORLD DATA
96.2%
Sensitivity (95% CI: 87.0% - 99.5%) · WLC 88.7% · Non-inferior
64
Patients enrolled
100%
Sensitivity lesions <5mm
HEADLINE RESULTS · RAISE02
HEADLINE RESULTS · RAISE02
“ I have observed CystoAID® transform from a research idea to a fully CE-marked clinical tool. The speedy trajectory is impressive. During our pre-clinical collaboration, I witnessed the potential of CystoAID® to improve cystoscopy procedures."
Jørgen Bjerggaard Jensen, DMSc
Professor, consultant urologist